Characteristics of patients with recurring lymphoma
| Characteristic . | All patients . | Evaluable patients with PET . |
|---|---|---|
| No. of patients | 117 | 101 |
| Sex, no. M/F | 69/48 | 59/42 |
| Median age, y (range) | 54 (19-76) | 53 (19-68) |
| Refractory disease, no. | 35 | 30 |
| Recurrent disease, no. | 82 | 61 |
| Median time with DFI, mo (range) | 14 (3-201) | 10 (3-144) |
| HL, no. | 26 | 23 |
| NHL, no. | 91 | 78 |
| DLBCL, no. | 60 | 53 |
| MCL, no. | 9 | 7 |
| FLIII, no. | 9 | 7 |
| PTCL, no. | 3 | 3 |
| ALCL, no. | 2 | 2 |
| Other, no. | 8 | 6 |
| Stage at relapse, no. | ||
| I-II | 39 | 33 |
| III-IV | 78 | 68 |
| sAA-IPI score, no. (%) | ||
| 0 | 7 (7.7) | 6 (7.7) |
| 1 | 26 (28.6) | 21 (26.9) |
| 2 | 48 (52.7) | 43 (55.1) |
| 3 | 10 (11.0) | 8 (10.3) |
| sHRS score, no. (%) | ||
| 0 | 5 (19.2) | 4 (17.4) |
| 1 | 12 (46.2) | 12 (52.2) |
| 2 | 6 (23.1) | 6 (26.1) |
| 3 | 3 (11.5) | 1 (4.3) |
| Characteristic . | All patients . | Evaluable patients with PET . |
|---|---|---|
| No. of patients | 117 | 101 |
| Sex, no. M/F | 69/48 | 59/42 |
| Median age, y (range) | 54 (19-76) | 53 (19-68) |
| Refractory disease, no. | 35 | 30 |
| Recurrent disease, no. | 82 | 61 |
| Median time with DFI, mo (range) | 14 (3-201) | 10 (3-144) |
| HL, no. | 26 | 23 |
| NHL, no. | 91 | 78 |
| DLBCL, no. | 60 | 53 |
| MCL, no. | 9 | 7 |
| FLIII, no. | 9 | 7 |
| PTCL, no. | 3 | 3 |
| ALCL, no. | 2 | 2 |
| Other, no. | 8 | 6 |
| Stage at relapse, no. | ||
| I-II | 39 | 33 |
| III-IV | 78 | 68 |
| sAA-IPI score, no. (%) | ||
| 0 | 7 (7.7) | 6 (7.7) |
| 1 | 26 (28.6) | 21 (26.9) |
| 2 | 48 (52.7) | 43 (55.1) |
| 3 | 10 (11.0) | 8 (10.3) |
| sHRS score, no. (%) | ||
| 0 | 5 (19.2) | 4 (17.4) |
| 1 | 12 (46.2) | 12 (52.2) |
| 2 | 6 (23.1) | 6 (26.1) |
| 3 | 3 (11.5) | 1 (4.3) |
DLCL indicates diffuse large B-cell lymphoma; MCL, mantle cell lymphoma; FLIII, follicular lymphoma grade III; PTCL, peripheral T-cell lymphoma; ALCL, anaplastic large cell lymphoma; DFI, disease-free interval between last treatment and relapse.